Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population
Poster of Distinction Award Granted to TARGET-IBD Research
News provided by
Share this article
Share this article
DURHAM, N.C., May 23, 2021 /PRNewswire/ Research presented today at Digestive Disease Week (DDW) 2021 evaluated the prevalence and predictors of immunomodulator use as concomitant therapy with two commonly prescribed biologics, vedolizumab (Entyvio) or ustekinumab (Stelara), in patients with inflammatory bowel disease (IBD). Data from Target RWE s TARGET-IBD large longitudinal cohort
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort was selected for the Poster of Distinction Award.
DNN-Gartentipp: Obstgehölze durch Kopulation veredeln
dnn.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dnn.de Daily Mail and Mail on Sunday newspapers.
Demenzforschung: Holografische Endoskope aus Jena schauen ins Gehirn
mdr.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mdr.de Daily Mail and Mail on Sunday newspapers.